FDA accepts Roche’s Tecentriq sBLA for priority review

The US Food and Drug Administration (FDA) has accepted Roche’s (ROG: SIX) supplemental Biologics License Application (sBLA) filing for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs).

Atezolizumab is intended in for use combination with chemotherapy in stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer, a type of tumor characterized by high mutation rates. The FDA has granted Priority Review and is expected to make a decision on the approval by October 9, 2026, the Swiss pharma giant noted.